Patents Assigned to STEMMEDICARE CO., LTD.
  • Publication number: 20260008998
    Abstract: The use of immune-tolerized fetal stem cell-derived extracellular vesicles as a pharmaceutical composition for hair loss treatment is disclosed. The pharmaceutical composition of immune-tolerized fetal stem cell-derived extracellular vesicles for hair loss treatment contains noggin, sclerostin domain-containing protein 1 (SOSTDC1), fibroblast growth factor-7 (FGF-7), and platelet-derived growth factor-alpha (PDGF-?) to promote the conversion of hair in the catagen phase into hair in the anagen phase.
    Type: Application
    Filed: January 6, 2025
    Publication date: January 8, 2026
    Applicant: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho LEE
  • Publication number: 20250270504
    Abstract: Disclosed are immune-tolerized fetal stem cell-derived extracellular vesicles. These are immune-tolerized fetal stem cell-derived extracellular vesicles contain fibroblast growth factor-2 (FGF-2), fibroblast growth factor-7 (FGF-7), insulin-like growth factor-1 (IGF-1), transforming growth factor-beta 1 (TGF-?1), bone morphogenetic protein-4 (BMP-4), bone morphogenetic protein-5 (BMP-5), and bone morphogenetic protein-7 (BMP-7), and include HLA-G protein.
    Type: Application
    Filed: February 21, 2025
    Publication date: August 28, 2025
    Applicant: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho LEE
  • Patent number: 12150962
    Abstract: A fetal stem cell-derived extracellular vesicle has immune tolerance properties. The extracellular vesicle containing a fetal stem cell-derived primal immunoglobulin contains various natural antibodies and complement proteins which can immediately respond to foreign infectious agents such as viruses, bacteria, pathogens, etc., and thus can effectively treat and prevent infectious diseases through an enhanced innate immune system. Methods are disclosed for preparing the fetal stem cell-derived extracellular vesicle.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: November 26, 2024
    Assignee: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho Lee
  • Patent number: 11771720
    Abstract: The present invention relates to anticancer extracellular vesicles, a preparation method therefor, and an anticancer composition comprising same. Immune-tolerized extracellular vesicles containing LDHB and PGC-1? of the present invention provide cancer treatment, suppression of cancer metastasis, and cancer prevention technologies by normalizing cancer cell-specific aerobic glycolysis energy metabolic pathway in which lactate and hydrogen ions, which form a tumor microenvironment favorable for immune evasion, proliferation, metastasis and invasion of cancer cells, are produced, thereby enabling tumors to be effectively removed by means of the immune system of a patient.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: October 3, 2023
    Assignee: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho Lee
  • Publication number: 20230165902
    Abstract: A fetal stem cell-derived extracellular vesicle has immune tolerance properties. The extracellular vesicle containing a fetal stem cell-derived primal immunoglobulin contains various natural antibodies and complement proteins which can immediately respond to foreign infectious agents such as viruses, bacteria, pathogens, etc., and thus can effectively treat and prevent infectious diseases through an enhanced innate immune system. Methods are disclosed for preparing the fetal stem cell-derived extracellular vesicle.
    Type: Application
    Filed: July 16, 2021
    Publication date: June 1, 2023
    Applicant: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho LEE
  • Patent number: 11566220
    Abstract: The disclosure relates to the establishment of a cell line having immune tolerance property using an optimal temperature profiling technique under a human body-like environment, and use thereof. The stem cell line exhibits immune tolerance property as they consecutively secret and express HLA-G proteins, and the culture medium of the stem cells contains a large amount of proteins capable of recovering various physiological functions and extracellular vesicles, and thus, the novel cell line or a culture medium thereof can be effectively used in various industries such as medicines and cosmetics.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: January 31, 2023
    Assignee: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho Lee
  • Patent number: 11077145
    Abstract: The present invention relates to the method for mass production of mesenchymal stem cell-derived proteins including various growth factors and cytokines, a mesenchymal stem cell conditioned medium containing a large amount of protein and produced by the above production method, cosmetic composition and pharmaceutical composition including the above conditioned medium for skin regeneration, anti-wrinkle, alopecia treatment, prevention of hair loss and promotion of hair growth.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: August 3, 2021
    Assignee: STEMMEDICARE CO., LTD.
    Inventor: Jang Ho Lee